Transmucosal delivery devices with enhanced uptake
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61P-025/04
A61K-031/485
A61K-009/70
A61K-009/00
A61K-031/4468
출원번호
US-0198961
(2016-06-30)
등록번호
US-9597288
(2017-03-21)
발명자
/ 주소
Finn, Andrew
Vasisht, Niraj
출원인 / 주소
BioDelivery Sciences International, Inc.
대리인 / 주소
McCarter & English LLP
인용정보
피인용 횟수 :
0인용 특허 :
106
초록▼
The present invention provides methods for enhancing transmucosal uptake of a medicament, e.g., fentanyl or buprenorphine, to a subject and related devices. The method includes administering to a subject a transmucosal drug delivery device comprising the medicament. Also provided are devices suitabl
The present invention provides methods for enhancing transmucosal uptake of a medicament, e.g., fentanyl or buprenorphine, to a subject and related devices. The method includes administering to a subject a transmucosal drug delivery device comprising the medicament. Also provided are devices suitable for transmucosal administration of a medicament to a subject and methods of their administration and use. The devices include a medicament disposed in a mucoadhesive polymeric diffusion environment and a barrier environment.
대표청구항▼
1. A method for delivering fentanyl to a human comprising: administering a mucoadhesive biodegradable drug delivery device for transmucosal delivery to the oral mucosa of said human, the device comprising: a biodegradable mucoadhesive layer comprising fentanyl disposed in a polymeric diffusion envir
1. A method for delivering fentanyl to a human comprising: administering a mucoadhesive biodegradable drug delivery device for transmucosal delivery to the oral mucosa of said human, the device comprising: a biodegradable mucoadhesive layer comprising fentanyl disposed in a polymeric diffusion environment, wherein the polymeric diffusion environment has a pH of between about 6 and about 8.5; anda polymeric barrier environment disposed adjacent to the mucoadhesive layer, wherein a unidirectional diffusion gradient of fentanyl is provided upon application to a buccal surface,wherein the overall bioavailability of fentanyl is at least about 60%; andwherein the fentanyl is delivered in less than about 30 minutes. 2. The method of claim 1, wherein the overall bioavailability of fentanyl is at least about 70%. 3. The method of claim 1, wherein the polymeric diffusion environment comprises at least one film-forming water-erodible adhesive polymer and at least one bioadhesive polymer. 4. The method of claim 1, wherein said polymeric barrier environment comprises at least one film-forming water-erodible polymer. 5. The method of claim 1, wherein the polymeric diffusion environment has a pH of between about 7 to about 7.5. 6. The method of claim 1, wherein the mucoadhesive biodegradable drug delivery device further comprises an opioid antagonist. 7. The method of claim 1, wherein the biodegradable drug delivery device further comprises a third layer or coating. 8. The method of claim 1, wherein the polymeric diffusion environment has a pH buffered to between about 6 and about 8.5. 9. The method of claim 1, wherein the polymeric diffusion environment has a pH buffered to between about 7 to about 7.5. 10. The method of claim 8, wherein the overall bioavailability of fentanyl is at least about 70%. 11. The method of claim 8, wherein the polymeric diffusion environment comprises at least one film-forming water-erodible adhesive polymer and at least one bioadhesive polymer. 12. The method of claim 8, wherein said polymeric barrier environment comprises at least one film-forming water-erodible polymer. 13. The method of claim 8, wherein the mucoadhesive biodegradable drug delivery device further comprises an opioid antagonist. 14. The method of claim 8, wherein the biodegradable drug delivery device further comprises a third layer or coating. 15. A device for delivering fentanyl to a human, the device comprising: a biodegradable mucoadhesive layer comprising fentanyl disposed in a polymeric diffusion environment, wherein the polymeric diffusion environment has a pH of between about 6 and about 8.5; anda polymeric barrier environment disposed adjacent to the mucoadhesive layer, wherein a unidirectional diffusion gradient of fentanyl is provided upon application to a buccal surface of a subject,wherein upon application to a buccal surface, the overall bioavailability of fentanyl is at least about 60%; andwherein the fentanyl is delivered in less than about 30 minutes. 16. The device of claim 15, wherein the overall bioavailability of fentanyl is at least about 70%. 17. The device of claim 15, wherein the polymeric diffusion environment comprises at least one film-forming water-erodible adhesive polymer and at least one bioadhesive polymer. 18. The device of claim 15, wherein said polymeric barrier environment comprises at least one film-forming water-erodible polymer. 19. The device of claim 15, wherein the polymeric diffusion environment has a pH of between about 7 to about 7.5. 20. The device of claim 15, wherein the mucoadhesive biodegradable drug delivery device further comprises an opioid antagonist. 21. The device of claim 15, wherein the biodegradable drug delivery device further comprises a third layer or coating. 22. The device of claim 15, wherein the polymeric diffusion environment has a pH buffered to between about 6 and about 8.5. 23. The device of claim 15, wherein the polymeric diffusion environment has a pH buffered to between about 7 to about 7.5. 24. The device of claim 22, wherein the overall bioavailability of fentanyl is at least about 70%. 25. The device of claim 22, wherein the polymeric diffusion environment comprises at least one film-forming water-erodible adhesive polymer and at least one bioadhesive polymer. 26. The device of claim 22, wherein said polymeric barrier environment comprises at least one film-forming water-erodible polymer. 27. The device of claim 22, wherein the mucoadhesive biodegradable drug delivery device further comprises an opioid antagonist. 28. The device of claim 27, wherein said opioid antagonist is naloxone. 29. The device of claim 22, wherein the biodegradable drug delivery device further comprises a third layer or coating. 30. A method for treating pain, the method comprising: adhering a mucoadhesive biodegradable drug delivery device to a buccal surface of a human, the device comprising: a biodegradable mucoadhesive layer comprising a therapeutically effective amount of fentanyl for treating pain disposed in a polymeric diffusion environment, wherein the polymeric diffusion environment has a pH buffered to between about 6 and about 8.5; anda polymeric barrier environment disposed adjacent to the mucoadhesive layer wherein a unidirectional diffusion gradient of fentanyl is provided upon application to the buccal surface,wherein the transmucosal delivery of fentanyl is at least about 50% by direct buccal absorption,wherein the overall bioavailability of fentanyl is at least about 70%; andwherein the fentanyl is delivered in less than about 30 minutes.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (106)
Lee Eun S. (Redwood City CA) Goetz Victor (Philadelphia PA), Abusable substance dosage form having reduced abuse potential.
Babaian Eduard A. (Moscow SUX) Gerasimova Galina A. (Moscow SUX) Davydov Anatoly B. (Moscow SUX) Utyamyshev Rustam I. (Moscow SUX) Khromov Gennady L. (Moscow SUX) Metelitsa Vladimir I. (Moscow SUX) V, Antianginal film and method of treating ischemic heart disease.
Rel Bernhard (Knigstein/Taunus DEX) Petri Walter (Niedernhausen/Taunus DEX), Base for mucosal and denture adhesive pastes, a process for the preparation thereof, and pastes having this base.
Schiraldi Michael T. (East Brunswick NJ) Perl Martin M. (Brooklyn NY) Rubin Howard (Rockaway NJ), Bioadhesive extruded film for intra-oral drug delivery and process.
Stanley Theodore H. (Salt Lake City UT) Hague Brian (West Valley City UT), Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments.
Kim Jung J. (Anyang-shi KRX) Lee Woo Y. (Anyang-shi KRX) Ahn Jong W. (Seoul KRX) Han Sang H. (Suwon-shi KRX), Medicinal adhesive for percutaneous administration.
Wong Ooi (Fremont CA) Farinas Kathleen C. (San Francisco CA) Cleary Gary W. (Menlo Park CA) Chiang Chia-Ming (Foster City CA) Xia Jun (Redwood City CA), Method and device for providing nicotine replacement therapy transdermally/transbuccally.
Nagai Tsuneji (Chofu JPX) Machida Yoshiharu (Kawasaki JPX) Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX), Method and preparation for administration to the mucosa of the oral or nasal cavity.
Nagai Tsuneji (Chofu JPX) Machida Yoshiharu (Kawasaki JPX) Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX), Method and preparation for administration to the mucosa of the oral or nasal cavity.
Cilento Rodolfo D. (North Brunswick NJ) Frank Margaret A. (Lawrenceville NJ) Fairbrother John E. (Wales NJ GBX) Freeman Frank M. (Lawrenceville NJ), Method of preparing adhesive dressings containing a pharmaceutically active ingredient.
Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX) Yamashita Gentaro (Tachikawa JPX) Nagai Tsuneji (Taito JPX), Method of treating an injured part on the oral mucosa and the covering material for use thereof.
Berner Bret (Scarsdale NY) Ebert Charles (Salt Lake City UT) Mazzenga Gerard C. (New City NY) Otte John H. (Monsey NY), Mixed solvent mutually enhanced transdermal therapeutic system.
Newsham E. A. (Derbyshire GBX) Forrester Jeffrey W. (Merseyside GBX) Rowley Duncan J. (Merseyside GBX), Moistureless oral drug delivery formulation and method for preparing same.
Moro, Daniel G.; Callahan, Howard; Nowotnik, David, Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds.
Kizawa Hidenori (Tokyo JPX) Fujiyama Norimasa (Tokyo JPX) Kobayashi Jitsuo (Kanagawa JPX) Ito Akinori (Niigata JPX), Mucous membrane-adhering film preparation and process for its preparation.
Tucker Mark J. (Round Steps ; High Street Stow-on-the-Wold ; Gloucester GL54 1DL GBX) Tucker Mark R. (P.O. Box 23530 Bahrain BHX), Occlusive body for administering a physiologically active substance.
Penkler Lawrence John,ZAX ; De Kock Lueta-Ann,ZAX ; Whittaker Darryl Vanstone,ZAX, Pharmaceutical composition containing acid addition salt of basic drug.
Venkateshwaran Srinivasan ; Fikstad David ; Ebert Charles D., Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents.
Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX) Yamashita Gentaro (Koganei JPX), Slow-releasing medical preparation to be administered by adhering to a wet mucous surface.
Hsu, Tsung-Min; Macy, Russell; Luo, Eric C., Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers.
Heiber Sonia J. (Salt Lake City UT) Ebert Charles D. (Salt Lake City UT) Dave Sirish C. (Salt Lake City UT), Transmucosal delivery of macromolecular drugs.
Heiber Sonia J. (Salt Lake City UT) Ebert Charles D. (Salt Lake City UT) Dave Sirish C. (Salt Lake City UT), Transmucosal delivery of macromolecular drugs.
Biegajski James E. (Foster City CA) Venkatraman Subbu S. (Palo Alto CA) Scott Ann M. (Mountain View CA), Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavi.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.